Watch list: quality stocks beat volatility in a bull run
Investors seek steadier paths as stocks hover near record highs. Brian Milligan of Ave Maria Growth Fund urges sticking to quality leaders, buying on weakness, and avoiding value traps. He cites Lowe’s pullback and Grace as examples of durable franchises set to benefit from housing demand and a weaker dollar.
MENTIONED IN THIS ARTICLE
Brian Milligan
Ave Maria
Milligan
Lowe’s
Wall Street
Grace
SigFig Investors Show Varied 6-Month Returns Across US
SigFig data highlight America’s online investors tracking portfolios. More than half a million users with about 200 billion dollars in assets reveal mixed results with millionaire users underperforming non millionaires over six months. Major holdings include Apple Inc. and broad equity allocations.
MENTIONED IN THIS ARTICLE
SigFig
Bed Bath & Beyond Cuts Forecast Amid Sales Slump
Express shares slid after Bed Bath & Beyond trimmed its full year outlook and reported lower same store sales and traffic. The retailer hired an external auditor to review its Indian supplier over pricing of sheets tied to premium Egyptian cotton, a move Target had also criticized.
MENTIONED IN THIS ARTICLE
Express
Bed Bath & Beyond
Target
Fitbit cleared of Jawbone data usage claims boosts no stock loss
Fitbit, under scrutiny over alleged use of Jawbone data, was cleared with shares holding gains after robust Best Buy results. The market watched volatility via the CBOE VIX at 1.03 and the S&P 500 P/E trailing earnings metric, while four week price activity showed a small 0.07 rise to 14.81 with a 0.5 percent cig component.
MENTIONED IN THIS ARTICLE
Fitbit
Jawbone
Endo International
ENDP
Wynn Resorts
WYNN
Garmin Garmin
GRMN
Goldman
Mylan NV
MYL
Mallinckrodt
MNK
Alcoa
Vertex Pharmaceuticals
VRTX
Icron Micron Technology
Vanguard
Vanguard InstPlus
Vanguard Totintl
Fidelity Contra Oo Energy American Funds IncomerAm
Grthama m
Capincbua m
Q Materials
ETF
Telcom
US Oil Fund LP
BardPath
ARM
Bankrate.com
NeWmont Mining
NEM
Newmont
Glencore
Frankfurt
Hong Kong
Japan
Nikkei
London
Mexico City
Morningstar
DOW Jones
THE
Associated Press
USA Today.com
Money Diated Press
Pfizer to buy AstraZeneca anti infection drugs for up to 2.6 billion
Pfizer agrees to an upfront 550 million dollars plus potentially 1 billion in milestones and royalties for rights to late stage anti infection drugs from AstraZeneca. The deal includes Zavicetta and other therapies, with additional payments of 175 million in 2019, up to 250 million on development benchmarks and up to 600 million on sales and royalties. Pfizer shares closed down 0.7 percent at 34.82 dollars amid a broader buying spree including a 14 billion dollar purchase of Medication.
MENTIONED IN THIS ARTICLE
Pfizer
United Kingdom
AstraZeneca
Medication
Zavicetta
Pfizer Essential Health Group
John Young
Also Mentioned on This Page
America
USA
AAPL
SIGF
MAJOR
Disa Rey
Kroger
Rite Aid
Walgreens
Nui Ad
S&p 500
Standard & Poor's
Russell Russell
Indf
Advance Auto Parts
AAP
FLIR
eBay
Whole Foods Market
WFM
Chipotle Mexican Grill
CMG
Pelpprxi Delphi Automotive
DLPH
Mobileye
Starbucks
SBUX
Cowan
Simon Property Group
SPG
Freeport-McMoRan
FCX
Miner
Perfoi
CBOE
S&p
Turz
Bloomberg
Oe Ee LY IM Pfizer
Janu
This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!